Glaucoma

Ophthalmology 0 original drugs

Novel Drugs

Reformulations

Drug Targets

Ophthalmology indication. Glaucoma has 0 FDA-approved novel treatments, with 67 active industry clinical trials across 11 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Phase 3 Readouts Pro

10 active Phase 3 trials with confidence-graded completion dates.

Full calendar →

Q3 2026

Bimatoprost SR

AbbVie

Estimated · aging NCT03891446

Q4 2027

HUC3-637

Huons Co., Ltd.

Estimated · fresh NCT07335211

Q1 2028

Gen 2 Travoprost Intracameral Implant

Glaukos Corporation

Estimated · fresh NCT07075718

Unlock 7 more readouts with confidence-graded estimates

Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Glaucoma Treatments by Mechanism

Top 4 mechanisms across 19 industry trials with a known mechanism of action.

See full pipeline →

Prostaglandin Analog

16 trials 1 active 9 sponsors

Carbonic Anhydrase Inhibitor

1 trials 1 sponsor

Vascular Endothelial Growth Factor Inhibitor

1 trials 1 sponsor

Beta-1 adrenergic receptor/Beta-2 adrenergic receptor/Carbonic Anhydrase II

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Glaucoma Clinical Pipeline by Phase

359 industry-sponsored trials across 98 sponsors

View full landscape →

Showing 87 of 87 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Glaukos Corporation	—	—	RECRUITING	2026-08	NCT06848946
Glaukos Corporation	Travoprost Intraocular Implant	—	RECRUITING	2027-05	NCT06066645
AbbVie	—	—	ACTIVE NOT RECRUITING	2030-07	NCT05821855
Laboratorios Poen	Dorzolamide / Timolol Ophthalmic Solution	—	COMPLETED	2024-11-04	NCT05857267
Pharmasoft	Mexidol	—	COMPLETED	2023-11-29	NCT06437639
Aerie Pharmaceuticals	Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution	—	COMPLETED	2023-03-22	NCT05283395
AbbVie	—	—	COMPLETED	2021-05-13	NCT03654885
Glaukos Corporation	—	—	COMPLETED	2019-12-16	NCT01252914
Glaukos Corporation	—	—	COMPLETED	2019-11-08	NCT02868190
Glaukos Corporation	Topical travoprost	—	COMPLETED	2019-11-08	NCT02873806
Aerie Pharmaceuticals	Netarsudil Ophthalmic Solution 0.02%	—	COMPLETED	2019-07-26	NCT03808688
Glaukos Corporation	Travoprost	Prostaglandin Analog [EPC]	COMPLETED	2019-03-28	NCT01444040
AbbVie	brimonidine tartrate/timolol malate Ophthalmic Solution	—	COMPLETED	2018-07-25	NCT02863705
AbbVie	bimatoprost 0.03% plus timolol 0.5%	—	COMPLETED	2018-06-21	NCT02571712
Alcon Research	Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension	—	COMPLETED	2018-02-27	NCT02419508
Novartis	brinzolamide 1%/brimonidine 0.2% fixed combination	—	COMPLETED	2017-12-04	NCT03150160
Laboratorios Poen	Latanoprost Ophthalmic Product	—	COMPLETED	2017-10-06	NCT03331770
Alcon Research	Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension	—	COMPLETED	2017-01-14	NCT02770248
Glaukos Corporation	Travoprost	Prostaglandin Analog [EPC]	COMPLETED	2017-01	NCT01443988
AbbVie	bimatoprost 0.01% ophthalmic solution	—	COMPLETED	2016-12-06	NCT01298700
Glaukos Corporation	—	—	COMPLETED	2016-07	NCT01252888
Laboratoires Thea	Monoprost	—	COMPLETED	2016-07	NCT02017327
Glaukos Corporation	—	—	COMPLETED	2016-07	NCT01252862
AqueSys, Inc.	—	—	COMPLETED	2016-02-09	NCT02006693
Alcon, a Novartis Company	Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension	—	COMPLETED	2015-12	NCT02325518
Alcon Research	Beta-blocker monotherapy	—	COMPLETED	2015-05	NCT02003391
AbbVie	bimatoprost 0.01%	—	COMPLETED	2014-12	NCT02097719
AbbVie	bimatoprost 0.01%	—	COMPLETED	2014-10	NCT01881126
Alcon Research	Travoprost Ophthalmic Solution 0.004%	—	COMPLETED	2014-06	NCT01995136
Alcon Research	Travoprost 0.004% ophthalmic solution	—	COMPLETED	2014-06	NCT01664039
Alcon Research	Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension	—	COMPLETED	2014-05	NCT01937312
Alcon Research	Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension	—	COMPLETED	2014-04	NCT01937299
EyeTechCare	—	—	COMPLETED	2014-03	NCT01592955
Alcon Research	Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension	—	COMPLETED	2014-03	NCT01978600
Aeon Astron Europe B.V.	Use of Mitomycin-C (MMC) in trabeculectomy	—	COMPLETED	2013-12	NCT01440751
Sensimed AG	—	—	COMPLETED	2013-09	NCT01938287
Glaukos Corporation	—	—	COMPLETED	2013-09	NCT00911924
AbbVie	travoprost ophthalmic solution 0.004%	—	COMPLETED	2013-07	NCT01547598
Alcon Research	Brinzolamide 1% / timolol 0.5% maleate fixed combination	—	COMPLETED	2013-06	NCT01415401
Alcon Research	Travoprost 0.004% BAK-free	—	COMPLETED	2013-05	NCT01510145
Alcon Research	Brinzolamide 1% / timolol 0.5% Fixed Combination	—	COMPLETED	2013-04	NCT01263444
Alcon Research	Brinzolamide/timolol maleate fixed combination	—	COMPLETED	2013-02	NCT01518244
AbbVie	0.15% Brimonidine Tartrate	—	COMPLETED	2013-02	NCT02003534
Alcon Research	Travoprost 0.004%	—	COMPLETED	2013-02	NCT01493427
AbbVie	Bimatoprost 0.01%	—	COMPLETED	2013-01	NCT01594970
AbbVie	0.03% Bimatoprost	—	COMPLETED	2012-12	NCT02020512
Alcon Research	Travoprost 0.004%+Timolol 0.5% ophthalmic solution	—	COMPLETED	2012-11	NCT01327599
Alcon Research	Brinzolamide 1.0% + Timolol 0.5% ophthalmic suspension	—	COMPLETED	2012-10	NCT01340014
AbbVie	0.1% brimonidine tartrate ophthalmic solution	—	COMPLETED	2012-10	NCT01525173
Glaukos Corporation	latanoprost/timolol	—	COMPLETED	2012-09	NCT00913029
FinnMedi Oy	Tafluprost 0.0015%	—	COMPLETED	2012-06	NCT01369771
Alcon Research	Travoprost 0.004% ophthalmic solution	—	COMPLETED	2012-06	NCT01464424
Alcon Research	Travoprost 0.004%/timolol maleate 0.5% fixed combination	—	COMPLETED	2012-03	NCT01336569
Alcon Research	Brinzolamide 1% and timolol 0.5% fixed combination eye drops	—	COMPLETED	2012-03	NCT01484951
AbbVie	bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution	—	COMPLETED	2012-02-14	NCT01243567
Alcon Research	Brinzolamide 10 mg/ml/Timolol 5 mg/ml eye drops suspension	—	COMPLETED	2012-01	NCT00800540
Alcon Research	Elazop (Azarga)	—	COMPLETED	2011-12	NCT01055366
AbbVie	bimatoprost ophthalmic solution 0.01%	—	COMPLETED	2011-10	NCT01253902
Alcon Research	Azarga (brinzolamide 1% / timolol 0.5%)	—	COMPLETED	2011-07	NCT01111890
AbbVie	Bimatoprost 0.03%	—	COMPLETED	2011-06-24	NCT02061683
Alcon Research	Brinzolamide/Timolol Maleate Fixed Combination (AZARGA)	—	COMPLETED	2011-05	NCT01471158
AbbVie	Bimatoprost 0.01%	—	COMPLETED	2011-03	NCT01833741
Alcon Research	Travoprost 0.004%/Timolol 0.5% Fixed Combination eye drops solution (Duotrav®)	—	COMPLETED	2011-02	NCT01230736
Alcon Research	Travoprost 0.004% / Timolol maleate 0.5%	—	COMPLETED	2011-01	NCT00759239
AbbVie	fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution	—	COMPLETED	2010-09	NCT01170884
Alcon Research	Brinzolamide/Timolol Maleate Fixed Combination (AZARGA)	—	COMPLETED	2010-08	NCT00966576
Taiwan Otsuka Pharm. Co., Ltd	carteolol (Mikelan), timolol (Timoptol), latanoprost (Xalatan)	—	COMPLETED	2010-08	NCT00972426
Alcon Research	Azopt	Carbonic Anhydrase Inhibitor [EPC]	COMPLETED	2010-07	NCT00761995
Alcon Research	Travoprost 0.004% ophthalmic solution (TRAVATAN)	—	COMPLETED	2010-03	NCT00966940
AbbVie	fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution	—	COMPLETED	2010-01	NCT00811564
AbbVie	fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution	—	COMPLETED	2009-12	NCT00811850
AbbVie	Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%	—	COMPLETED	2009-12	NCT00735449
Alcon Research	DuoTrav	—	COMPLETED	2009-11	NCT00828906
Alcon Research	Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)	—	COMPLETED	2009-08	NCT00708422
Laboratoires Thea	Geltim LP 1 mg/g	—	COMPLETED	2009-07	NCT01155219
Alcon Research	Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)	—	COMPLETED	2009-05	NCT00798759
Vistakon Pharmaceuticals	Timolol Maleate in Sorbate	—	COMPLETED	2008-12	NCT00804648
Sight Sciences, Inc.	Latanoprost plus adjunctive glaucoma medication	—	TERMINATED	2025-01-20	NCT06407973
Laboratorios Sophia S.A de C.V.	Dorzolamide-timolol-brimonidine and latanoprost	—	TERMINATED	2023-11-23	NCT04702789
Alcon Research	Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension	—	TERMINATED	2018-07-13	NCT02730871
Sensimed AG	—	—	TERMINATED	2014-02	NCT01983579
Alcon Research	Travoprost/Timolol Maleate BAK-Free Fixed Combination	—	TERMINATED	2013-11	NCT01514721
Alcon Research	Brinzolamide/timolol maleate fixed combination	—	TERMINATED	2012-08	NCT01514734
Sensimed AG	—	—	TERMINATED	2012-04	NCT01263535
AbbVie	brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution	—	TERMINATED	2012-02	NCT01151904
Alcon Research	Travoprost 0.004%/Timolol 0.5% Fixed Combination (DuoTrav)	—	WITHDRAWN	2013-02	NCT01696383
Alcon Research	Travoprost/timolol fixed combination (Travacom)	—	WITHDRAWN	2012-01	NCT01510132

Showing 100 of 116 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Huons Co., Ltd.	HUC3-637	—	RECRUITING	2027-11	NCT07335211
YS Life Science Co., Ltd.	Bimatoprost ophthalmic solution 0.01% YSBP	—	RECRUITING	2027-11-01	NCT07661329
Glaukos Corporation	Gen 2 Travoprost Intracameral Implant	—	RECRUITING	2028-03	NCT07075718
Glaukos Corporation	Gen 2 Travoprost Intracameral Implant	—	RECRUITING	2028-06	NCT07495852
AbbVie	—	—	RECRUITING	2028-11	NCT06822738
SpyGlass Pharma, Inc.	Bimatoprost Implant System	—	RECRUITING	2029-03-31	NCT07218783
SpyGlass Pharma, Inc.	Bimatoprost Implant System	—	RECRUITING	2029-05-31	NCT07218796
Qlaris Bio, Inc.	Latanoprost (0.005%)	—	RECRUITING	2026-07-01	NCT07354516
Omikron Italia S.r.l.	Citicoline eye drops 2%	—	RECRUITING	2026-04-01	NCT05710198
Amneal Pharmaceuticals, LLC	Test - Bimatoprost 0.01% Ophthalmic Solution	—	RECRUITING	2022-12	NCT05401357
Santen Pharmaceutical Co., Ltd.	DE-117B Eye Drops	—	ACTIVE NOT RECRUITING	2026-08-31	NCT06666855
AbbVie	Bimatoprost SR	—	ACTIVE NOT RECRUITING	2026-07	NCT03891446
Glaukos Corporation	iDose TR	Prostaglandin Analog [EPC]	ACTIVE NOT RECRUITING	2024-03-18	NCT06061718
Ache Laboratorios Farmaceuticos S.A.	Product DNN.31.19.026	—	NOT YET RECRUITING	2028-03	NCT07617532
Alcon Research	Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution	—	COMPLETED	2026-04-06	NCT07082816
AbbVie	—	—	COMPLETED	2026-02-04	NCT05411198
AbbVie	Bimatoprost (SR)	—	COMPLETED	2025-08-08	NCT03850782
Nicox Ophthalmics, Inc.	NCX 470 0.1%	—	COMPLETED	2025-04-11	NCT04630808
Nicox Ophthalmics, Inc.	NCX 470	—	COMPLETED	2025-03-17	NCT05938699
Laboratoires Thea	Bimatoprost Ophthalmic	—	COMPLETED	2024-03-07	NCT05397600
EMS	BREMEN eye drops	—	COMPLETED	2023-07-31	NCT03235232
Tarsier Pharma	TRS01	—	COMPLETED	2023-06-29	NCT05042609
Sun Pharmaceutical Industries Limited	Brinzolamide ophthalmic suspension	—	COMPLETED	2022-12-29	NCT05022004
Nicox Ophthalmics, Inc.	NCX 470 0.065% (initial phase of trial)	—	COMPLETED	2022-09-16	NCT04445519
Mankind Pharma Limited	Test - Bimatoprost 0.01% Ophthalmic Solution	—	COMPLETED	2022-08-11	NCT04890106
Glaukos Corporation	Sham surgery + active-comparator eye drops	—	COMPLETED	2022-06-10	NCT03868124
AbbVie	Bimatoprost SR	—	COMPLETED	2022-05-14	NCT04285580
Glaukos Corporation	Sham surgery + active-comparator eye drops	—	COMPLETED	2022-04-05	NCT03519386
AbbVie	—	—	COMPLETED	2022-03-18	NCT03362931
Padagis LLC	Brinzolamide/brimonidine ophthalmic suspension	—	COMPLETED	2022-03-11	NCT04944290
AbbVie	Bimatoprost SR	—	COMPLETED	2021-11-24	NCT02507687
Aerie Pharmaceuticals	Netarsudil ophthalmic solution 0.02%	—	COMPLETED	2021-07-09	NCT04620135
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.	Levobetaxolol eye drops	—	COMPLETED	2021-07-01	NCT02617459
Laboratoires Thea	Bimatoprost	Prostaglandin Analog [EPC]	COMPLETED	2021-02-03	NCT03825380
AbbVie	Bimatoprost SR	—	COMPLETED	2021-01-26	NCT02636946
Sun Pharma Advanced Research Company Limited	Brimonidine Tartrate Ophthalmic Suspension	—	COMPLETED	2020-12-01	NCT03450629
Aerie Pharmaceuticals	Netarsudil/Latanoprost 0.02%/0.005%	—	COMPLETED	2020-11-06	NCT03284853
Padagis LLC	Brinzolamide 1% ophthalmic suspension	—	COMPLETED	2020-02-26	NCT04024072
Ocular Therapeutix, Inc.	Travoprost	Prostaglandin Analog [EPC]	COMPLETED	2019-03-30	NCT02914509
Bayer	Aflibercept (EYLEA, BAY86-5321)	—	COMPLETED	2019-02-14	NCT03639675
AbbVie	Bimatoprost SR	—	COMPLETED	2018-10-25	NCT02250651
Jadran Galenski laboratorij d.d.	Dorzotimol eye drops, 20 mg/mL + 5 mg/mL	—	COMPLETED	2018-09-17	NCT05973318
AbbVie	Bimatoprost SR	—	COMPLETED	2018-02-19	NCT02247804
Taejoon Pharmaceutical Co., Ltd.	TJO-002	—	COMPLETED	2017-12-28	NCT03419975
Aerie Pharmaceuticals	PG324 Ophthalmic Solution 0.02%/0.005%	—	COMPLETED	2017-05-17	NCT02558400
Jadran Galenski laboratorij d.d.	Dorzol 20 mg/ml	—	COMPLETED	2017-04-05	NCT05973305
Laboratorios Sophia S.A de C.V.	PRO-122	—	COMPLETED	2017-03-01	NCT03257813
Aerie Pharmaceuticals	PG324 Ophthalmic Solution 0.02%/0.005%	—	COMPLETED	2017-03	NCT02674854
Santen Pharmaceutical Co., Ltd.	DE-117 ophthalmic solution low	—	COMPLETED	2017-02-10	NCT02623738
Aerie Pharmaceuticals	AR-13324 Ophthalmic Solution 0.02%	—	COMPLETED	2016-12	NCT02246764
Aerie Pharmaceuticals	AR-13324 Ophthalmic Solution 0.02%	—	COMPLETED	2016-12	NCT02558374
Alcon Research	Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL fixed combination eye drops, suspension	—	COMPLETED	2016-11-01	NCT02339584
Inotek Pharmaceuticals Corporation	trabodenoson 4.5% BID	—	COMPLETED	2016-11	NCT02565173
Bayer	Aflibercept (Eylea, BAY 86-5321)	—	COMPLETED	2016-06-16	NCT02396316
Actavis Inc.	Test-Brinzolamide 1% Ophthalmic suspension	—	COMPLETED	2016-04	NCT02512042
Aerie Pharmaceuticals	AR-13324 Ophthalmic Solution 0.02%	—	COMPLETED	2016-03	NCT02207621
Novartis	ranibizumab	Vascular Endothelial Growth Factor Inhibitor [EPC]	COMPLETED	2016-01-08	NCT01908816
Laboratoires Thea	T2347	—	COMPLETED	2015-11	NCT02278614
Bausch & Lomb Incorporated	BOL-303259-X	—	COMPLETED	2015-06-02	NCT01749904
Bausch & Lomb Incorporated	BOL-303259-X	—	COMPLETED	2015-05	NCT01749930
Bausch & Lomb Incorporated	Latanoprostene bunod	—	COMPLETED	2015-04-02	NCT01895972
Aerie Pharmaceuticals	Timolol maleate Ophthalmic Solution 0.5% BID	—	COMPLETED	2015-03	NCT02207491
Otsuka Pharmaceutical Co., Ltd.	OPC-1085EL ophthalmic solution	—	COMPLETED	2015-03	NCT02105272
Nephron Pharmaceuticals Corporation	T-2345	—	COMPLETED	2015-01	NCT02059278
Otsuka Pharmaceutical Co., Ltd.	OPC-1085EL ophthalmic solution	—	COMPLETED	2015-01	NCT02105285
AqueSys, Inc.	—	—	COMPLETED	2014-11	NCT01640756
AbbVie	bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)	—	COMPLETED	2014-09	NCT01217606
AbbVie	Bimatoprost 0.01%	—	COMPLETED	2014-05	NCT01830140
Alcon Research	Travoprost 0.004% PQ ophthalmic solution	—	COMPLETED	2014-03	NCT01652664
Glaukos Corporation	—	—	COMPLETED	2013-12	NCT01052558
AbbVie	bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)	—	COMPLETED	2013-09	NCT01241240
Merck	Preservative-Free Tafluprost or vehicle	—	COMPLETED	2013-05-09	NCT01254604
Alcon Research	Brinzolamide 1% / Timolol 0.5% fixed combination ophthalmic suspension	—	COMPLETED	2013-01	NCT01357616
Alcon Research	Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension	—	COMPLETED	2013-01	NCT01309204
Alcon Research	Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension	—	COMPLETED	2013-01	NCT01310777
Bausch & Lomb Incorporated	brinzolamide 1% ophthalmic suspension	—	COMPLETED	2012-09	NCT01722604
Santen Pharmaceutical Co., Ltd.	DE-111 ophthalmic solution	—	COMPLETED	2012-09	NCT01342094
Santen Pharmaceutical Co., Ltd.	DE-111 ophthalmic solution	—	COMPLETED	2012-09	NCT01342081
Santen Oy	Timolol/ FDC/ Placebo/ Tafluprost	—	COMPLETED	2012-09	NCT01292460
Alcon Research	Travoprost ophthalmic solution, 0.003%	—	COMPLETED	2012-08	NCT01453855
AbbVie	bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution	—	COMPLETED	2012-08	NCT01216943
Sun Pharma Advanced Research Company Limited	SPARC0913	—	COMPLETED	2012-06	NCT00945958
Alcon Research	Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension	—	COMPLETED	2012-06	NCT01297920
Sun Pharma Advanced Research Company Limited	SPARC0912	—	COMPLETED	2012-05	NCT00947661
Santen Oy	Timolol and Tafluprost	—	COMPLETED	2012-04	NCT01306461
Alcon Research	Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension	—	COMPLETED	2012-03	NCT01297517
AbbVie	bimatoprost /timolol formulation A fixed combination ophthalmic solution	—	COMPLETED	2012-02	NCT01177098
Alcon Research	Travoprost 0.004%/Timolol 0.5%	—	COMPLETED	2011-11	NCT00872651
Alcon Research	Travoprost APS 40 micrograms/ml eye drop solution	—	COMPLETED	2011-05	NCT00892762
AbbVie	Bimatoprost 0.03% Formulation B Ophthalmic Solution	—	COMPLETED	2011-04-29	NCT01099774
Laboratoires Thea	T2345	—	COMPLETED	2010-12	NCT01156012
Alcon Research	Travoprost/Timolol Maleate Fixed Combination solution	—	COMPLETED	2010-11	NCT00928590
Santen Oy	tafluprost	Prostaglandin Analog [EPC]	COMPLETED	2010-10	NCT01087671
Merck	Preservative-Free Tafluprost	—	COMPLETED	2010-09-17	NCT01026831
Alfred E. Tiefenbacher (GmbH & Co. KG)	Dorzolamide 2 % eye drops solution	—	COMPLETED	2010-02	NCT00878917
Alcon Research	Travoprost 0.004% (POLYQUAD-preserved) Eye Drops, Solution	—	COMPLETED	2010-01	NCT00848536
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Timolol	Beta-1 adrenergic receptor/Beta-2 adrenergic receptor/Carbonic Anhydrase II	COMPLETED	2009-11	NCT00716859
Alcon Research	Anecortave Acetate Sterile Suspension, 30 mg/mL	—	COMPLETED	2009-09	NCT00691717
Alcon Research	Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)	—	COMPLETED	2009-09	NCT00761319
Alcon Research	Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)	—	COMPLETED	2009-05	NCT00690794

Showing 100 of 117 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
PolyActiva Pty Ltd	Latanoprost 0.005% Ophthalmic Solution	—	RECRUITING	2026-11-15	NCT06964191
IVIEW Therapeutics Inc.	GVB-2001-high dose	—	RECRUITING	2027-12-30	NCT06921317
Qlaris Bio, Inc.	QLS-111 Ophthalmic Solution (0.015%)	—	RECRUITING	2026-06	NCT07354477
Amydis Inc.	AMDX-2011P	—	RECRUITING	2024-11	NCT06223048
AbbVie	AGN-193408 SR	—	ACTIVE NOT RECRUITING	2029-04	NCT04499248
Bausch & Lomb Incorporated	BL1107 Low dose	—	ACTIVE NOT RECRUITING	2026-05	NCT07168902
SpyGlass Pharma, Inc.	Bimatoprost Implant System (High Dose)	—	ACTIVE NOT RECRUITING	2025-01-31	NCT06120842
Laboratoires Thea	Kinezodianone R hydrochloride	—	ACTIVE NOT RECRUITING	2024-12-31	NCT05389267
Qlaris Bio, Inc.	QLS-111 ophthalmic solution (0.015%)	—	COMPLETED	2026-02-23	NCT06030193
Alcon Research	AR-17043 Ophthalmic Solution	—	COMPLETED	2025-11-14	NCT06441643
Perfuse Therapeutics, Inc.	PER-001 Intravitreal Implant - Low Dose	—	COMPLETED	2025-04-20	NCT05822245
Qlaris Bio, Inc.	QLS-111, 0.015%	—	COMPLETED	2024-12-20	NCT06249152
Laboratoires Thea	T4090 0.2%	—	COMPLETED	2024-11-21	NCT06394973
D. Western Therapeutics Institute, Inc.	H-1337 0.6%	—	COMPLETED	2024-08-29	NCT05913232
Qlaris Bio, Inc.	Experimental: QLS-111 ophthalmic solution, (0.015%)	—	COMPLETED	2024-08-20	NCT06016972
Skye Bioscience, Inc.	SBI-100 Ophthalmic Emulsion, 0.5%	—	COMPLETED	2024-02-22	NCT06144918
Ocular Therapeutix, Inc.	OTX-TIC low dose Travoprost Intracameral Implant	—	COMPLETED	2024-01-24	NCT05335122
Glaukos Corporation	Travoprost Intracameral Implant exchanged at Month 12	—	COMPLETED	2023-11-02	NCT06582732
Pharmasoft	Mexidol	—	COMPLETED	2023-09-07	NCT06903156
Qlaris Bio, Inc.	QLS-101 ophthalmic solution, 2.0 %	—	COMPLETED	2023-01-25	NCT05495269
VivaVision Biotech, Inc	VVN539 Ophthalmic Solution 0.02%	—	COMPLETED	2022-12-22	NCT05451329
Qlaris Bio, Inc.	QLS-101	—	COMPLETED	2022-08-26	NCT04857827
Qlaris Bio, Inc.	QLS-101ophthalmic solution 1%	—	COMPLETED	2022-06-06	NCT04947124
Betaliq, Inc.	Nebivolol Ophthalmic Suspension 1 Percent	—	COMPLETED	2022-03-31	NCT04910100
Glaukos Corporation	Travoprost	Prostaglandin Analog [EPC]	COMPLETED	2022-02-28	NCT04615403
Qlaris Bio, Inc.	QLS-101	—	COMPLETED	2022-02-17	NCT04830397
Santen Inc.	DE-126 Ophthalmic Solution 0.002% QD	—	COMPLETED	2021-12-07	NCT04742283
MediPrint Ophthalmics, Inc.	LL-BMT1	—	COMPLETED	2021-02-16	NCT04747808
Bausch & Lomb Incorporated	WB007 0.05%	—	COMPLETED	2021-01-31	NCT04149899
EyePoint Pharmaceuticals, Inc.	Latanoprost ophthalmic solution	—	COMPLETED	2020-11-05	NCT04405245
Aerie Pharmaceuticals	Netarsudil Ophthalmic Solution 0.01%	—	COMPLETED	2019-09-19	NCT03844945
Ocuphire Pharma, Inc.	Phentolamine Mesylate Ophthalmic Solution 1%	—	COMPLETED	2019-09-11	NCT03960866
Nicox Ophthalmics, Inc.	NCX 470	—	COMPLETED	2019-08-23	NCT03657797
Bausch & Lomb Incorporated	brinzolamide 1% ophthalmic suspension	—	COMPLETED	2018-11-17	NCT03896633
Allysta Pharmaceutical	H-1337 [1]	—	COMPLETED	2018-08-15	NCT03452033
pH Pharma	PHP-201 0.25% ophthalmic solution	—	COMPLETED	2018-05-02	NCT03106532
Glaukos Corporation	Travoprost Intraocular Implant, high elution	—	COMPLETED	2017-08-01	NCT02754596
Inotek Pharmaceuticals Corporation	trabodenoson 6.0% / latanoprost 0.005% QD	—	COMPLETED	2017-05-24	NCT02829996
ViSci Ltd.	VS101 Insert Dose A	—	COMPLETED	2017-05	NCT02129673
ForSight Vision5, Inc.	Fixed Combination	—	COMPLETED	2016-12-31	NCT02742649
Can-Fite BioPharma	CF101	—	COMPLETED	2016-12	NCT01033422
Mati Therapeutics Inc.	Latanoprost Punctal Plug Delivery System (L-PPDS)	—	COMPLETED	2016-12	NCT02014142
Alcon Research	MGV354 ophthalmic suspension	—	COMPLETED	2016-09-20	NCT02743780
Aerie Pharmaceuticals	Netarsudil ophthalmic solution 0.02%	—	COMPLETED	2016-09	NCT02874846
ForSight Vision5, Inc.	Bimatoprost	Prostaglandin Analog [EPC]	COMPLETED	2016-08-11	NCT02537015
AbbVie	bimatoprost 20 µg generation 2	—	COMPLETED	2016-07-27	NCT01157364
Peregrine Ophthalmic	POLAT-001	—	COMPLETED	2016-04	NCT02466399
ForSight Vision5, Inc.	Bimatoprost	Prostaglandin Analog [EPC]	COMPLETED	2015-12-31	NCT02143843
Ocular Therapeutix, Inc.	OTX-TP	—	COMPLETED	2015-09	NCT02312544
ForSight Vision5, Inc.	Bimatoprost	Prostaglandin Analog [EPC]	COMPLETED	2015-08-31	NCT02358369
Sylentis, S.A.	1 drop of 0.375% SYL040012 (bamosiran)	—	COMPLETED	2015-08	NCT02250612
Quark Pharmaceuticals	QPI-1007 Injection	—	COMPLETED	2015-06	NCT01965106
Santen Inc.	DE-117 Low Dose ophthalmic solution	—	COMPLETED	2015-01	NCT02179008
Ono Pharmaceutical Co., Ltd.	ONO-9054	—	COMPLETED	2014-12	NCT02083289
Alcon Research	Dose Level A / Brinzolamide 1% ophthalmic suspension	—	COMPLETED	2014-11	NCT02140060
Amakem, NV	AMA0076	—	COMPLETED	2014-11	NCT02136940
ForSight Vision5, Inc.	Bimatoprost	Prostaglandin Analog [EPC]	COMPLETED	2014-09-30	NCT01915940
Inotek Pharmaceuticals Corporation	Trabodenoson	—	COMPLETED	2014-08	NCT01917383
Aerie Pharmaceuticals	PG324 Ophthalmic Solution 0.01%	—	COMPLETED	2014-06	NCT02057575
Alleanza Pharmaceuticals, Inc.	ALZ-1101	—	COMPLETED	2014-01	NCT01896180
Bausch & Lomb Incorporated	BOL-303259-X	—	COMPLETED	2013-12	NCT01707381
AbbVie	Fixed-Combination Bimatoprost/Brimonidine	—	COMPLETED	2013-12	NCT01863953
Ivantis, Inc.	prestudy topical glaucoma medications	—	COMPLETED	2013-11	NCT03065036
Amakem, NV	AMA0076	—	COMPLETED	2013-07	NCT01693315
Aerie Pharmaceuticals	PG286 Ophthalmic Solution 0.5%	—	COMPLETED	2013-06	NCT01789736
Aerie Pharmaceuticals	AR-13324 Ophthalmic Solution 0.01%	—	COMPLETED	2013-05	NCT01731002
Sylentis, S.A.	SYL040012	—	COMPLETED	2013-05	NCT01739244
Aerie Pharmaceuticals	AR-12286 Ophthalmic Solution 0.7%	—	COMPLETED	2013-04	NCT01699464
Kubota Vision Inc.	OPA-6566	—	COMPLETED	2012-10	NCT01410188
Mati Therapeutics Inc.	Latanoprost-PPDS	—	COMPLETED	2012-09	NCT01481077
Mati Therapeutics Inc.	Latanoprost-PPDS	—	COMPLETED	2012-09	NCT01481051
Aerie Pharmaceuticals	AR-12286 0.5% Ophthalmic Solution	—	COMPLETED	2012-08	NCT01330979
Altheos, Inc.	ATS907	—	COMPLETED	2012-08	NCT01668524
Aerie Pharmaceuticals	AR-13324 Ophthalmic Solution 0.01%	—	COMPLETED	2012-07	NCT01528787
Lexicon Pharmaceuticals	LX7101 (0.125%)	—	COMPLETED	2012-06	NCT01528111
Roche	PRM-151	—	COMPLETED	2012-04-30	NCT01064817
Aerie Pharmaceuticals	0.25% AR-12286 / 0.004% travoprost	—	COMPLETED	2012-04	NCT01474135
Sylentis, S.A.	SYL040012	—	COMPLETED	2012-03	NCT01227291
Aerie Pharmaceuticals	Latanoprost 0.005%	—	COMPLETED	2011-12	NCT01302249
Inotek Pharmaceuticals Corporation	INO-8875	—	COMPLETED	2011-12	NCT01123785
Alcon Research	Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension	—	COMPLETED	2011-11	NCT01426867
Santen Inc.	DE-112	—	COMPLETED	2011-11	NCT01279083
Alcon Research	AL-54478 0.005%	—	COMPLETED	2011-10	NCT01318252
AbbVie	AGN-210669	—	COMPLETED	2011-10	NCT01291108
Mati Therapeutics Inc.	Latanoprost-PPDS	—	COMPLETED	2011-08	NCT01229982
Santen SAS	Latanoprost	Prostaglandin Analog [EPC]	COMPLETED	2011-06	NCT01254370
AbbVie	AGN-210961 Formulation 1	—	COMPLETED	2011-05	NCT01110499
Alcon Research	Travoprost Ophthalmic Solution, 0.00013%	—	COMPLETED	2011-04	NCT01298687
AbbVie	400 ug Brimonidine Implant	—	COMPLETED	2011-01	NCT00693485
Aerie Pharmaceuticals	AR-12286 0.5% ophthalmic solution	—	COMPLETED	2010-08	NCT01060579
Pfizer	PF-04217329	—	COMPLETED	2010-06	NCT00934089
Mati Therapeutics Inc.	Formulation E1 of L-PPDS	—	COMPLETED	2010-05	NCT00967811
Santen Inc.	DE-104 medium concentration	—	COMPLETED	2010-05	NCT00868894
Alcon Research	Travoprost 0.004%	—	COMPLETED	2010-05	NCT01114893
Mati Therapeutics Inc.	Latanoprost Punctal Plug Delivery System	—	COMPLETED	2010-04	NCT01037036
AbbVie	AGN-210669 ophthalmic solution, 0.1%	—	COMPLETED	2010-04	NCT01001195
Merck	timolol/dorzolamide combination	—	COMPLETED	2010-03-12	NCT00832377
Vistakon Pharmaceuticals	High Dose Drug Device	—	COMPLETED	2010-02	NCT01016691
Mati Therapeutics Inc.	Latanoprost punctal plug	—	COMPLETED	2009-12	NCT00845299
Mati Therapeutics Inc.	Latanoprost-PPDS	—	COMPLETED	2009-12	NCT00820300

Showing 39 of 39 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
EyeD Pharma	TimoD implant	—	RECRUITING	2027-01	NCT07036510
Life Biosciences Inc.	—	—	RECRUITING	2027-05	NCT07290244
Amneal Pharmaceuticals, LLC	Bimatoprost Ophthalmic Solution, 0.01%	—	RECRUITING	2025-03-01	NCT06267274
PolyActiva Pty Ltd	—	—	ACTIVE NOT RECRUITING	2027-02-15	NCT06964061
Rheon Medical SA	—	—	ACTIVE NOT RECRUITING	2025-09-01	NCT07480603
SpyGlass Pharma, Inc.	BIM-DRS Low Dose	—	NOT YET RECRUITING	2027-02-28	NCT07641296
PolyActiva Pty Ltd	PA5108 Latanoprost FA SR Ocular Implant	—	COMPLETED	2025-05-13	NCT04060758
D. Western Therapeutics Institute, Inc.	H-1337 1.0%	—	COMPLETED	2024-10-14	NCT06572397
ONL Therapeutics	ONL1204 Ophthalmic solution (Dose A)	—	COMPLETED	2024-04-09	NCT05160805
PolyActiva Pty Ltd	100ng/day PA5346 Latanoprost FA SR Ocular Implant	—	COMPLETED	2023-06-12	NCT05333419
Chong Kun Dang Pharmaceutical	D565	—	COMPLETED	2022-10-18	NCT05207761
Ocular Therapeutix, Inc.	OTX-TIC	—	COMPLETED	2021-05-24	NCT04360174
PolyActiva Pty Ltd	PA5108	—	COMPLETED	2020-06-15	NCT03604328
Aerpio Therapeutics	AKB-9778 Ophthalmic Solution	—	COMPLETED	2019-12-15	NCT04284514
Laboratorios Sophia S.A de C.V.	PRO-122	—	COMPLETED	2019-08-30	NCT03966365
Laboratorios Sophia S.A de C.V.	PRO 179	—	COMPLETED	2019-07-02	NCT03965052
Annexon, Inc.	2.5mg ANX007	—	COMPLETED	2019-06-03	NCT04188015
Annexon, Inc.	ANX007	—	COMPLETED	2018-08-03	NCT03488550
Takeda	SHP639 (n=60)	—	COMPLETED	2018-05-30	NCT03131167
Dompé Farmaceutici S.p.A	rhNGF	—	COMPLETED	2018-05	NCT02855450
Roche	0.01% RO7058584	—	COMPLETED	2017-12-15	NCT03293992
Santen Oy	Preservative free tafluprost opthalmic solution	—	COMPLETED	2017-05-29	NCT02102750
Isarna Therapeutics GmbH	TGF-β2 antisense oligonucleotide	—	COMPLETED	2016-08	NCT02406833
Roche	Latanoprost	Prostaglandin Analog [EPC]	COMPLETED	2016-07-28	NCT02622334
Palobiofarma SL	PBF-677	—	COMPLETED	2016-04	NCT02639975
ForSight Vision5, Inc.	VISION5 Product	—	COMPLETED	2014-06	NCT01943721
Otsuka Pharmaceutical Co., Ltd.	OPC-1085EL ophthalmic solution	—	COMPLETED	2014-05	NCT02108288
Croma-Pharma GmbH	—	—	COMPLETED	2014-04	NCT01887873
Ocular Therapeutix, Inc.	OTX-TPa ~4µg/day over 2 mos. with natural tears drops	—	COMPLETED	2014-03	NCT01845038
Amakem, NV	AMA0076	—	COMPLETED	2013-12	NCT02003547
Merz Pharmaceuticals GmbH	MRZ-99030 eye drops 5mg/mL	—	COMPLETED	2013-12	NCT01714960
Alcon Research	Travoprost ophthalmic solution, 0.004% (new formulation)	—	COMPLETED	2013-07	NCT01658839
Ono Pharma USA Inc	ONO-9054	—	COMPLETED	2013-05	NCT01670266
AbbVie	timolol ophthalmic solution 0.5%	—	COMPLETED	2010-12	NCT01215786
Sylentis, S.A.	SYL040012	—	COMPLETED	2010-06	NCT00990743
Merck	INS117548	—	COMPLETED	2009-05	NCT00767793
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	latanoprost	Prostaglandin Analog [EPC]	COMPLETED	2009-03	NCT00638742
EyeD Pharma	TimoD implant	—	TERMINATED	2025-06-26	NCT06321562
Care Team Solutions	—	—	WITHDRAWN	2014-12	NCT02031380

Novel Glaucoma Drugs by Company (New molecular entities)

No novel drugs found for this indication.

Reformulations (12 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.